IntroductionMore than 170 million individuals have hepatitis C virus (HCV) infection worldwide, and approximately four million people are newly infected with HCV every year. Up to 80% of patients with HCV infection proceed to chronic hepatitis C (CHC), which can ultimately lead to the development of liver cirrhosis and hepatocellular carcinoma . Previously, the standard treatment of CHC was a combination therapy with weekly pegylated interferon‐α (Peg‐IFN‐α) injection and daily oral ribavirin (RBV) . For example, a large randomised trial reported that the combination therapy of Peg‐IFN‐α and RBV increased sustained viral response (SVR) up to 52% , which is defined as the absence of detectable HCV RNA 24 weeks after completion of antiviral therapy for CHC. Before first‐generation direct‐acting antivirals (DAAs) were licensed for use in HCV genotype 1 infection in 2011, their combination for 24 or 48 weeks was the approved treatment for CHC .In the meantime, observational epidemiological studies have reported that there is an association between low levels of vitamin D and the risk of CHC. A retrospective cohort study with 468 study participants showed that the mean level of vitamin D in noncirrhosis CHC patients was 17 ng mL−1 and 25% of them had
Journal of Human Nutrition & Dietetics – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud